Moleculin Biotech Inc (MBRX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.76 (-2.82%), Market cap $0.01B, 52-week low–high $0.27 ~ $7.71.
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and W
Financial statements, price targets, institutional (13F) holdings and related news for Moleculin Biotech Inc are updated in real time on BlackAll Trade.
Moleculin Biotech Inc trades at $0.76 (-2.82%). Real-time quotes and charts are available on BlackAll Trade.
Moleculin Biotech Inc has a market cap of about $0.01B.
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annam